Royalty Pharma plc (RPRX) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-13.29M
Gain on disposal of discontinued operations
Gain on disposal of fixed assets
Noncash financing costs
Noncash inventory impairment
Noncash patent impairment
Noncash other income
Noncash decrease in accounts payable
Depreciation and amortization	4K
Noncash stock-based compensation	1.49M
Common stock issued for agreement not to compete
Series B Preferred Stock issued for consulting services
Increase in receivables
Increase in inventory
(Increase) decrease in prepaid expenses and other current assets	-74K
Increase (decrease) in accounts payable and accrued expenses	-609K
Net cash used in operating activities
Change in trading marketable securities
Capital expenditures
Purchase of technology rights and other assets
Proceeds from sale of PP&E
Cash acquired in purchase of FTI
Proceeds from sale of subsidiary, less $12,345 for operating losses during 1990 phase-out period
Proceeds from sale of the assets of FTI
Increase in net assets held for disposal
Net cash used in investing activities
Proceeds from issuance of common stock, net of offering costs	1.59M
Exercise of stock options & warrants
Proceeds from a shareholder transaction	0
Proceeds from issuance of preferred stock
Purchase of treasury stock
Proceeds from issuance of notes payable
Principal payments on notes payable
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents	-10.89M
Cash and cash equivalents at beginning of period	21.39M
Cash and cash equivalents at end of period	10.51M

Entities mentioned with RPRX

View All Entities